Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Loos, Martin ^a   Hedderich, Dennis M ^a   Ottenhausen, Malte ^a   Giese, Nathalia A ^b   Laschinger, Melanie ^a   Esposito, Irene ^a   Kleeff, Jörg ^a   Friess, Helmut ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B7 H3 ANTIGEN; CD8 ANTIGEN; LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG; CD276 PROTEIN, HUMAN; GAMMA INTERFERON; IMMUNOGLOBULIN RECEPTOR; LEUKOCYTE ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PANCREAS RESECTION; POSTOPERATIVE PERIOD; PROGNOSIS; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; UPREGULATION; ADOLESCENT; CARCINOMA; EVALUATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; PATHOLOGY; SURVIVAL; TUMOR CELL CULTURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; CARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON-GAMMA; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RECEPTORS, IMMUNOLOGIC; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 74549182599     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-463     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96. 10.3322/CA.2007.0010, 18287387.
2. Kleeff J, Michalski C, Friess H, Buchler MW. Pancreatic cancer: from bench to 5-year survival. Pancreas 2006, 33(2):111-118. 10.1097/01.mpa.0000229010.62538.f2, 16868475.
3. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004, 91(5):586-594. 10.1002/bjs.4484, 15122610.
4. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002, 8(8):793-800.
5. Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment. J Immunother 2006, 29(3):233-240. 10.1097/01.cji.0000199193.29048.56, 16699366.
6. Laheru D, Jaffee EM. Immunotherapy for pancreatic cancer - science driving clinical progress. Nat Rev Cancer 2005, 5(6):459-467. 10.1038/nrc1630, 15905855.
7. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005, 23:515-548. 10.1146/annurev.immunol.23.021704.115611, 15771580.
8. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996, 183(6):2533-2540. 10.1084/jem.183.6.2533, 2192613, 8676074.
9. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999, 5(12):1365-1369. 10.1038/70932, 10581077.
10. Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H, Chapoval AI, Flies DB, Bajorath J, Chen L. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 2003, 18(6):849-861. 10.1016/S1074-7613(03)00152-3, 12818165.
11. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004, 10(15):5094-5100. 10.1158/1078-0432.CCR-04-0428, 15297412.
12. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007, 13(7):2151-2157. 10.1158/1078-0432.CCR-06-2746, 17404099.
13. Loos M, Giese NA, Kleeff J, Giese T, Gaida MM, Bergmann F, Laschinger M, M WB, Friess H. Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer Lett 2008, 268(1):98-109. 10.1016/j.canlet.2008.03.056, 18486325.
14. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, Mizuno T, Yoriki R, Kashizuka H, Yane K, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005, 11(8):2947-2953. 10.1158/1078-0432.CCR-04-1469, 15837746.
15. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006, 66(7):3381-3385. 10.1158/0008-5472.CAN-05-4303, 16585157.
16. Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 2007, 56(8):1173-1182. 10.1007/s00262-006-0266-z, 17186290.
17. Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, Dong H, Sica GL, Zhu G, Tamada K, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2001, 2(3):269-274. 10.1038/85339, 11224528.
18. Suh WK, Gajewska BU, Okada H, Gronski MA, Bertram EM, Dawicki W, Duncan GS, Bukczynski J, Plyte S, Elia A, et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol 2003, 4(9):899-906. 10.1038/ni967, 12925852.
19. Luo L, Chapoval AI, Flies DB, Zhu G, Hirano F, Wang S, Lau JS, Dong H, Tamada K, Flies AS, et al. B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. J Immunol 2004, 173(9):5445-5450.
20. Lupu CM, Eisenbach C, Lupu AD, Kuefner MA, Hoyler B, Stremmel W, Encke J. Adenoviral B7-H3 therapy induces tumor specific immune responses and reduces secondary metastasis in a murine model of colon cancer. Oncol Rep 2007, 18(3):745-748.
21. Sun X, Vale M, Leung E, Kanwar JR, Gupta R, Krissansen GW. Mouse B7-H3 induces antitumor immunity. Gene Ther 2003, 10(20):1728-1734. 10.1038/sj.gt.3302070, 12939639.
22. Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, Lefvert AK, Wang X. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 2006, 53(2):143-151. 10.1016/j.lungcan.2006.05.012, 16782226.
23. Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, Scardino PT, Sharma P, Allison JP. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA 2007, 104(49):19458-19463. 10.1073/pnas.0709802104, 2148311, 18042703.
24. Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, Krambeck AE, McKenney ME, Karnes RJ, Blute ML, et al. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res 2007, 67(16):7893-7900. 10.1158/0008-5472.CAN-07-1068, 17686830.
25. Erkan M, Kleeff J, Esposito I, Giese T, Ketterer K, Buchler MW, Giese NA, Friess H. Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 2005, 24(27):4421-4432. 10.1038/sj.onc.1208642, 15856026.
26. Wang L, Fraser CC, Kikly K, Wells AD, Han R, Coyle AJ, Chen L, Hancock WW. B7-H3 promotes acute and chronic allograft rejection. Eur J Immunol 2005, 35(2):428-438. 10.1002/eji.200425518, 15682454.
27. Wu CP, Jiang JT, Tan M, Zhu YB, Ji M, Xu KF, Zhao JM, Zhang GB, Zhang XG. Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis. World J Gastroenterol 2006, 12(3):457-459.
28. Prasad DV, Nguyen T, Li Z, Yang Y, Duong J, Wang Y, Dong C. Murine B7-H3 is a negative regulator of T cells. J Immunol 2004, 173(4):2500-2506.
29. Ling V, Wu PW, Spaulding V, Kieleczawa J, Luxenberg D, Carreno BM, Collins M. Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss. Genomics 2003, 82(3):365-377. 10.1016/S0888-7543(03)00126-5, 12906861.
30. Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich BC, et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res 2008, 14(16):5150-5157. 10.1158/1078-0432.CCR-08-0536, 2789387, 18694993.
31. Hashiguchi M, Kobori H, Ritprajak P, Kamimura Y, Kozono H, Azuma M. Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses. Proc Natl Acad Sci USA 2008, 105(30):10495-10500. 10.1073/pnas.0802423105, 2492502, 18650384.
32. Kalvakolanu DV, Borden EC. An overview of the interferon system: signal transduction and mechanisms of action. Cancer Invest 1996, 14(1):25-53. 10.3109/07357909609018435, 8597888.
33. Bui JD, Carayannopoulos LN, Lanier LL, Yokoyama WM, Schreiber RD. IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. J Immunol 2006, 176(2):905-913.
34. Chang CJ, Chen YH, Huang KW, Cheng HW, Chan SF, Tai KF, Hwang LH. Combined GM-CSF and IL-12 gene therapy synergistically suppresses the growth of orthotopic liver tumors. Hepatology 2007, 45(3):746-754. 10.1002/hep.21560, 17326190.